A US district court in Delaware has scolded Galderma, telling the firm that it had “a theory but no proof,” as it firmly rejected the originator’s infringement claim against Lupin over two US patents shielding the Oracea (doxycycline) modified-release capsule treatment for rosacea.
In response, Galderma has filed an immediate appeal to the US Court of Appeals for the Federal Circuit.




